Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 33.2
(1.84%)
SEK 33.2
(1.84%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 18 Million SEK | -22.05% |
| 2022 | 12.78 Million SEK | 145.71% |
| 2021 | 5.2 Million SEK | 61.96% |
| 2020 | 3.21 Million SEK | 99.63% |
| 2019 | 1.6 Million SEK | 141.32% |
| 2018 | -3.89 Million SEK | -327.99% |
| 2017 | 1.7 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 122 Thousand SEK | -76.26% |
| 2024 Q3 | 13.77 Million SEK | 11189.34% |
| 2024 Q1 | 514 Thousand SEK | -90.54% |
| 2023 FY | 9.96 Million SEK | -22.05% |
| 2023 Q3 | 1.54 Million SEK | -75.38% |
| 2023 Q2 | 6.26 Million SEK | 45.62% |
| 2023 Q1 | 4.3 Million SEK | 179.78% |
| 2023 Q4 | 5.43 Million SEK | 252.24% |
| 2022 Q2 | 4.16 Million SEK | 22.84% |
| 2022 Q1 | 3.38 Million SEK | 182.18% |
| 2022 Q3 | 2.87 Million SEK | -30.84% |
| 2022 FY | 12.78 Million SEK | 145.71% |
| 2022 Q4 | 1.53 Million SEK | -46.58% |
| 2021 Q4 | 1.2 Million SEK | -39.68% |
| 2021 Q3 | 1.99 Million SEK | 62.4% |
| 2021 Q2 | 1.22 Million SEK | 56.38% |
| 2021 Q1 | 784 Thousand SEK | 297.97% |
| 2021 FY | 5.2 Million SEK | 61.96% |
| 2020 Q4 | 197 Thousand SEK | -82.01% |
| 2020 Q2 | 3.04 Million SEK | 1530.48% |
| 2020 FY | 3.21 Million SEK | 99.63% |
| 2020 Q1 | 187 Thousand SEK | -98.66% |
| 2020 Q3 | 1.09 Million SEK | -64.09% |
| 2019 Q3 | -8.59 Million SEK | -42.59% |
| 2019 Q4 | 13.91 Million SEK | 261.88% |
| 2019 FY | 1.6 Million SEK | 141.32% |
| 2019 Q2 | -6.02 Million SEK | -813.25% |
| 2019 Q1 | 845 Thousand SEK | 0.0% |
| 2018 FY | -3.89 Million SEK | -327.99% |
| 2017 FY | 1.7 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 107.233% |
| Ziccum AB (publ) | -21.56 Million SEK | 183.53% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 209.804% |
| BioArctic AB (publ) | 252.64 Million SEK | 92.872% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 2231.243% |
| Mendus AB (publ) | -100.65 Million SEK | 117.893% |
| Genovis AB (publ.) | 54.22 Million SEK | 66.788% |
| Intervacc AB (publ) | -93.57 Million SEK | 119.245% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 216.097% |
| Active Biotech AB (publ) | -46.48 Million SEK | 138.742% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 132.497% |
| Aptahem AB (publ) | -10.1 Million SEK | 278.223% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 105.601% |
| Kancera AB (publ) | -65.04 Million SEK | 127.688% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 113.378% |
| Fluicell AB (publ) | -26.87 Million SEK | 167.0% |
| Saniona AB (publ) | -81.06 Million SEK | 122.216% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 245.574% |
| Biovica International AB (publ) | -126.07 Million SEK | 114.285% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 142.369% |
| AcouSort AB (publ) | -17.48 Million SEK | 202.985% |
| Xintela AB (publ) | -57.23 Million SEK | 131.463% |
| Abliva AB (publ) | -96.54 Million SEK | 118.653% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 105.545% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 613.809% |
| OncoZenge AB (publ) | -15.9 Million SEK | 213.25% |
| Amniotics AB (publ) | -29.07 Million SEK | 161.944% |
| 2cureX AB (publ) | -36.36 Million SEK | 149.526% |
| CombiGene AB (publ) | -36.3 Million SEK | 149.605% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 223.012% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 104.685% |
| Camurus AB (publ) | 532.35 Million SEK | 96.617% |
| Corline Biomedical AB | -1.78 Million SEK | 1107.215% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 109.963% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 143.205% |
| I-Tech AB | 24.43 Million SEK | 26.298% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 102.284% |
| Cyxone AB (publ) | -21.66 Million SEK | 183.14% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 116.995% |
| Biosergen AB | -27.26 Million SEK | 166.052% |
| Cantargia AB (publ) | -290.01 Million SEK | 106.21% |
| NextCell Pharma AB | -43.17 Million SEK | 141.714% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 109.963% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 205.339% |
| Nanologica AB (publ) | -69.96 Million SEK | 125.741% |
| SynAct Pharma AB | -224.49 Million SEK | 108.022% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 140.766% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 175.181% |
| LIDDS AB (publ) | -40.67 Million SEK | 144.276% |
| Lipum AB (publ) | -37.25 Million SEK | 148.341% |
| BioInvent International AB (publ) | -369.94 Million SEK | 104.868% |
| Alzinova AB (publ) | -16.52 Million SEK | 209.0% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 107.106% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 381.688% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 115.65% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 189.424% |
| Simris Alg AB (publ) | -36.63 Million SEK | 149.158% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 112.287% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 105.801% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 116.237% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 255.706% |